In 2014, the European Medicines Agency (EMA) approved afamelanotide (Scenesse) for the treatment of EPP, making it the first melanocortin receptor agonist to receive regulatory approval for a medical condition
Research has shown that phosphoglycerate dehydrogenase (PHGDH), the enzyme that catalyzes the first reaction in the serine synthesis pathway, was highly upregulated in metastatic breast cancer and was correlated to short patient survival times [135, 136]
Don't let mono or other illnesses hold you back, schedule an appointment today and experience the benefits of IV vitamin
Monitoring pending requests, calling payers when decisions are overdue, and escalating urgent cases
Combining proper injection technique and site rotation with genetic and biomarker insights can support a more informed conversation with your provider about individualizing your GLP-1 treatment plan for both comfort and therapeutic response